A Brief Example of Strategic Alliance and Partnerships Development byGCI Research, Inc.

WHO WE ARE, WHAT WE DO, AREAS OF EXPERTISE, PRINCIPAL

Introducing a New Concept in Pathogen InactivationINTRODUCTION BY GCI RESEARCH, INC.AUGUST 2015

What this brief presentation covers:

•GCI Research, Inc.• Introduction of the concept• Invitation to learn more

What we do We help firms identify and establish mutually-beneficial strategic alliances and development partnerships that meet the needs of the parties involved.

Who we are

GCI Research is a boutique strategic planning, business development, and market research consultancy.

Areas of GCI’s Expertise and Experience in Healthcare

Areas of Expertise Product Areas 30+ CountriesAccountable careAdvertising effectivenessCompetitor analysisConcept testingCustomer relations Customer successGroup purchasing analysisHospital/group potential analysisManaged careMarket segmentation analysisMarket share & trends analysisMedia selectionNew product development & evaluationResource allocationResults trackingSearch engine optimizationStrategic planningSWOT analysis…among others

AdhesivesAnesthesiologyAngiography/ angioplastyBlood pressure monitoringBiopsies, cancer detection/diagnosisCardiologyChest drainageCritical/intensive careElectrocardiographyElectrosurgeryInfection controlInterventional radiologyObstetrics/gynecologyOrthopedicsPain managementPlastic surgeryProstate managementRespiratory careTemperature monitoringUrologyWound management…among others

ArgentinaBrazilCanadaCaribbeanChinaDenmarkEnglandFranceGermanyHollandHong KongIndonesiaIsraelItalyJapanKoreaMalaysiaMexicoPhilippinesRussiaUkraineUnited States…among others

Robert Dunford, Principal

• Business development manager, marketing director and senior analyst in five, market-share leading, Fortune-15 and smaller firms.

• Directed Voice of the Customer and Customer Success programs in the 37 business units of the $4 billion MPT Division of the Fortune-15 McKesson Company.

• Directed business development, market research, and marketing communications in the $400 million, Georgia-based Corporate Group of C.R. Bard, Inc.

• Created and directed marketing research, corporate planning, and business development functions of the $32 million NDM Division of Baxter International

• Fluent in Spanish, BA in Marketing, MBA from the University of Utah's David Eccles School of Business.

Introduction of the ConceptWHAT IT IS, WHAT IT DOES, WHAT IT DOESN’T DO, HOW IT WORKS

What it isThis is a new, patented technology for destroying blood pathogens, sterilizing blood and possibly plasma. It is FDA-approved for other medical applications.

What it DoesWithout actually contacting the blood or plasma, this new concept delivers pressure shockwaves to destroy blood pathogens. Applying this technology could bring a significant increase in the supply of blood and plasma world-wide and significantly reduce the impact of viruses such as Hep C.

What it Doesn’t DoThis non-invasive technology does not use chemicals or radioactive materials and does not produce heat.

•

o Dimensional differences among blood cells, bacteria and viruses, which make the thinner bacterium/virus membrane easier to be breached by shock waves.

o Structural differences that cause membranes for bacteria and viruses to be harder, when compared to very flexible membranes of blood cells.

o High sensitivity to sudden pressures changes (shock waves) for bacteria membranes that affects their mechanotransduction.

How it WorksFocused shock waves cause selective destruction of bacterium and virus membranes through:

The characteristics of focused shock waves include:

How it Works (cont.)

• Compressive pressure 1,000 times ultrasound magnitude

• Extremely rapid rise time

• Negative pressure causing cavitation

• Transient sonoluminescence

• Transient/localized high heat

• Total duration of 5 to 8 µs.

• Dosage (number of shocks, energy setting and frequency) is key for success

We Invite You to Learn MoreCONTACT INFORMATION

For more information contact:Robert R. Dunford, Managing DirectorGCI Research, Inc.396 Eagle Tiff Dr.Sugar Hill, GA 30518 U.S.A.• Call us at 678-288-9612 (office), 770-624-6924 (cell)• Write us at robdunford@gciresearch.com• Learn more about what we do at

www.gciresearch.com• Read what others say at

www.linkedin.com/in/robdunford